ALX Oncology to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025
ALX Oncology (Nasdaq: ALXO), a clinical-stage biotechnology company focused on developing immune-boosting cancer therapies, has announced it will release its fourth quarter and full year 2024 financial results on Thursday, March 6th, 2025, before market open. The company, which aims to treat cancer and extend patients' lives, noted that there will not be a teleconference accompanying the financial results press release.
ALX Oncology (Nasdaq: ALXO), un'azienda biotecnologica in fase clinica focalizzata sullo sviluppo di terapie oncologiche che potenziano il sistema immunitario, ha annunciato che rilascerà i suoi risultati finanziari del quarto trimestre e dell'anno intero 2024 giovedì 6 marzo 2025, prima dell'apertura del mercato. L'azienda, che mira a trattare il cancro e prolungare la vita dei pazienti, ha fatto sapere che non ci sarà una teleconferenza a supporto del comunicato stampa sui risultati finanziari.
ALX Oncology (Nasdaq: ALXO), una compañía biotecnológica en etapa clínica centrada en el desarrollo de terapias contra el cáncer que potencian el sistema inmunológico, ha anunciado que publicará sus resultados financieros del cuarto trimestre y del año completo 2024 el jueves 6 de marzo de 2025, antes de la apertura del mercado. La compañía, que tiene como objetivo tratar el cáncer y extender la vida de los pacientes, señaló que no habrá una teleconferencia acompañando el comunicado de prensa de los resultados financieros.
ALX Oncology (Nasdaq: ALXO)는 면역력을 강화하는 암 치료제를 개발하는 임상 단계의 생명공학 회사로, 2024년 4분기 및 연간 재무 결과를 2025년 3월 6일 목요일, 시장 개장 전에 발표할 것이라고 발표했습니다. 암 치료와 환자의 생명 연장을 목표로 하는 이 회사는 재무 결과 발표에 대한 전화 회의가 없을 것이라고 밝혔습니다.
ALX Oncology (Nasdaq: ALXO), une entreprise de biotechnologie en phase clinique axée sur le développement de thérapies anticancéreuses renforçant le système immunitaire, a annoncé qu'elle publiera ses résultats financiers du quatrième trimestre et de l'année 2024 le jeudi 6 mars 2025, avant l'ouverture des marchés. L'entreprise, qui vise à traiter le cancer et à prolonger la vie des patients, a précisé qu'il n'y aura pas de téléconférence accompagnant le communiqué de presse des résultats financiers.
ALX Oncology (Nasdaq: ALXO), ein biotechnologisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung von immunstärkenden Krebstherapien konzentriert, hat angekündigt, dass es seine Finanzergebnisse für das vierte Quartal und das gesamte Jahr 2024 am Donnerstag, den 6. März 2025, vor Markteröffnung veröffentlichen wird. Das Unternehmen, das darauf abzielt, Krebs zu behandeln und das Leben der Patienten zu verlängern, stellte fest, dass es keine Telefonkonferenz zur Begleitung der Pressemitteilung zu den Finanzergebnissen geben wird.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients’ lives, today announced plans to report its fourth quarter and full year 2024 financial results on Thursday, March 6th, 2025, before market open.
The company will not be hosting a teleconference in conjunction with its financial results press release.
About ALX Oncology
ALX Oncology (Nasdaq: ALXO) is a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients’ lives. ALX Oncology’s lead therapeutic candidate, evorpacept, has demonstrated potential to serve as a cornerstone therapy upon which the future of immuno-oncology can be built. Evorpacept is currently being evaluated across multiple ongoing clinical trials in a wide range of cancer indications. More information is available at www.alxoncology.com and on LinkedIn @ALX Oncology.
Investor Relations Contact:
Elhan Webb, CFA, IR Consultant
ewebb@alxoncology.com
Media Contact:
Audra Friis, Sam Brown, Inc.
audrafriis@sambrown.com
(917) 519-9577
FAQ
When will ALX Oncology (ALXO) release its Q4 and full year 2024 earnings?
Will ALXO host an earnings call for Q4 2024 results?
What is ALX Oncology's main business focus?
What stock exchange is ALXO listed on?
